Searchable abstracts of presentations at key conferences in endocrinology

ea0050oc1.3 | Early Career Oral Communications | SFEBES2017

Antioxidant pathway targeting as a therapeutic approach in adrenocortical carcinoma

Chortis Vasileios , Taylor Angela E. , Doig Craig L. , Meimaridou Eirini , Walsh Mark , Jenkinson Carl , Rodriguez-Blanco Giovanny , Jafri Alisha , Ronchi Cristina , Metherell Louise A. , Hebenstreit Daniel , Dunn Warwick B. , Arlt Wiebke , Foster Paul A.

Adrenocortical Carcinoma (ACC) is an aggressive malignancy with poor response to chemotherapy. Here we evaluated a potential new treatment target for ACC, focusing on the mitochondrial NADPH generator Nicotinamide Nucleotide Transhydrogenase (NNT). NNT has a central role within the mitochondrial antioxidant pathways, protecting cells from oxidative stress. Inactivating NNT mutations lead to isolated primary adrenal insufficiency, suggesting a selective vulnerability of adrenoc...

ea0086oc4.5 | Adrenal and Cardiovascular | SFEBES2022

Comparison of prednisolone and modified-release hydrocortisone capsules in the treatment of congenital adrenal hyperplasia: dose and disease control

Rees Aled , Merke Deborah , Arlt Wiebke , Pierriere Aude , Hirschberg Angelica , Juul Anders , Newell-Price John , Perry Colin , Prete Alessandro , Reisch Nicole , Stikkelbroeck Monica , Touraine Philippe , Coope Helen , Lewis Alexander , Porter John , Ross Richard

Introduction: First-line treatment for congenital adrenal hyperplasia (CAH) is hydrocortisone1. When adequate control is not achieved, prednisolone (or its prodrug prednisone) are often used. However, there has been no formal comparison of disease control in CAH comparing prednis(ol)one vs hydrocortisone and patients are often on a glucocorticoid dose that exceeds the guideline recommended dose of hydrocortisone (≤25 mg/day)1,2. We report an interim...

ea0065ec1.2 | Early Career Prize Lecture Translational | SFEBES2019

From bench to bedside and beyond: a novel therapy to improve wound healing in type 2 diabetes

Ajjan Ramzi , Hensor Elizabeth , Abbas Afroze , Galdo Francesco Del , Russell David , Shams Kave , Stewart Paul , Webber Lorraine , Pegg Lindsey , Freeman Adrian , Woods Janet , Eng Sookhoe , Taylor Angela , Arlt Wiebke , Tahrani Abd , Tiganescu Ana

The International Diabetes Federation estimates that type 2 diabetes mellitus (T2DM) will affect 642 million people by 2040. Chronically inflamed, hypoxic wounds are common in T2DM and represent a global unmet clinical need. Each year, diabetic foot ulcers cost the NHS £650 million and cause 1 in 200 UK deaths. This mortality is greater than colon, breast and prostate cancer combined. Glucocorticoids are used to treat a range of inflammatory conditions (e.g. asthma, eczem...

ea0065oc1.1 | Metabolism and Obesity | SFEBES2019

Intracrine activation of 11-oxygenated androgens by AKR1C3 modulates lipid metabolism in human female adipose tissue

Schiffer Lina , Sinclair Alexandra J , O'Reilly Michael W , Westgate Connar , Mashood Afeefa , Palmer Elliot , Gilligan Lorna C , Singhal Rishi , Taylor Angela E , Dunn Warwick B , Arlt Wiebke , Storbeck Karl-Heinz

Polycystic ovary syndrome (PCOS) affects 10% of women and is associated with an increased risk of type 2 diabetes and fatty liver disease. Androgen excess is an important driver of metabolic risk in PCOS. In adipose tissue from women with PCOS, increased activation of androstenedione (A4) to testosterone (T) by the enzyme AKR1C3 results in systemic lipotoxicity. Recent in-vitro studies also demonstrated that T and 11-ketotestosterone (11KT) activate the androgen recep...

ea0067o30 | Oral Presentations | EYES2019

AKR1D1 is a novel regulator of metabolic phenotype in human hepatocytes and is dysregulated in non-alcoholic fatty liver disease

Nikolaou Nikolaos , Gathercole Laura L , Marchand Lea , Althari Sara , Dempster Niall J , Green Charlotte J , van de Bunt Martijn , McNeil Catriona , Arvaniti Anastasia , Hughes Beverly A , Sgromo Bruno , Gillies Richard S , Ryan John , Arlt Wiebke , Hodson Leanne , Tomlinson Jeremy W

Objective: Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic syndrome. Steroid hormones and bile acids are potent regulators of hepatic carbohydrate and lipid metabolism. Steroid 5β-reductase (AKR1D1) is highly expressed in human liver where it inactivates steroid hormones and catalyzes a fundamental step in bile acid synthesis.Methods: Human liver biopsies were obtained from 34 obese patients and AKR1D1 mRNA expres...

ea0049oc3.5 | Receptors & Signalling | ECE2017

Accurate staging of non-alcoholic fatty liver disease through analysis of the urinary steroid metabolome

Moolla Ahmad , Amin Amin , Hughes Beverly , Arlt Wiebke , Hassan-Smith Zaki , Gilligan Lorna , Armstrong Matt , Newsome Philip , Shah Tahir , Van Gaal Luc , Verrijken An , Francque Sven , Grove Jane , Guha Neil , Aithal Guruprasad , Barnes Ellie , Biehl Michael , Tomlinson Jeremy

Introduction: Non-alcoholic fatty liver disease (NAFLD) is associated with dysregulated glucocorticoid metabolism. Advanced stages of NAFLD are associated with adverse outcome and current strategies to stage disease severity are still reliant upon liver biopsy. We have previously described changes to enzymatic pathways that regulate cortisol bioavailability; 11β-hydroxysteroid dehydrogenase type-1 (11β-HSD1) regenerates cortisol from inactive cortisone, and A-ring re...

ea0049gp180 | Pituitary | ECE2017

Outcome of non-functioning pituitary adenomas that regrow after primary treatment: a study from two large specialist UK centers

Tampourlou Metaxia , Ntali Georgia , Ahmed Shahzada , Arlt Wiebke , Ayuk John , Byrne James , Chavda Swarupsinh , Cudlip Simon , Gittoes Neil , Grossman Ashley , Mitchell Rosalind , O'Reilly Michael , Paluzzi Alessandro , Toogood Andrew , Wass John , Karavitaki Niki

Introduction: Despite the significant risk of regrowth of non-functioning pituitary adenomas (NFAs) after primary treatment, systematic data on the probability of further tumour progression and the effectiveness of management approaches are lacking.Aims: Assess the probability of further regrowth(s), predictive factors and outcomes of management approaches in patients with NFA diagnosed with adenoma regrowth after primary treatment (surgery combined or n...

ea0059p003 | Adrenal and steroids | SFEBES2018

Mass spectrometry-based assessment of childhood androgen excess in 487 consecutive patients

Mannion Pascoe , Elhassan Yasir , Smith Karen , Webster Rachel , Saraff Vrinda , Barrett Timothy , Shaw Nick , Krone Nils , Dias Renuka , Kershaw Melanie , Kirk Jeremy , Hogler Wolfgang , Krone Ruth , O'Reilly Michael , Arlt Wiebke , Idkowiak Jan

Background: Androgen excess in childhood is a common clinical presentation with potentially serious underlying pathology.Objectives and Design: We have examined the diagnostic utility of simultaneous measurement of serum dehydroepiandrosterone sulfate (DHEAS), androstenedione (A4), and testosterone (T) to delineate the biochemical signatures of conditions underlying paediatric hyperandrogenism in a large tertiary care referral centre (2013–2017). Se...

ea0038oc1.6 | Early Career Oral Communications | SFEBES2015

Urine steroid metabolomics as a diagnostic tool in primary aldosteronism

Lang Katharina , Beuschlein Felix , Biehl Michael , Dietz Anna , Riester Anna , Hughes Beverly A , O'Neil Donna M , Hahner Stefanie , Quinkler Marcus , Lenders Jacques W , Shackleton Cedric H L , Reincke Martin , Arlt Wiebke

Introduction: The regular diagnostic workup for primary aldosteronism (PA) can be very demanding and involves multiple invasive as well as time and cost intensive diagnostic tests. Here we have explored the value of urinary steroid metabolome analysis in the diagnosis and differential diagnosis of PA. Previously, urinary 3α,5β-tetrahydroaldosterone (THAldo) has been suggested as a reliable screening test for PA and serum 18-oxocortisol and 18-hydroxycortisol have bee...

ea0038oc3.4 | Steroids and adrenal | SFEBES2015

Urine steroid metabolomics as a novel diagnostic tool for early detection of recurrence in adrenocortical carcinoma

Chortis Vasileios , Bancos Irina , Lang Katharina , Hughes Beverly , O'Neil Donna , Taylor Angela , Fassnacht Martin , Bertherat Jerome , Beuschlein Felix , Quinkler Marcus , Vassiliadi Dimitra , Dennedy M Conall , Mannelli Massimo , Biehl Michael , Arlt Wiebke

Introduction: Adrenocortical carcinoma (ACC) is an aggressive malignancy with a high rate of recurrence. Regular post-operative follow-up imaging is necessary, but associated with high radiation exposure and frequent diagnostic ambiguity. Urine steroid metabolomics has recently been introduced as a novel diagnostic tool for the detection of adrenocortical malignancy in patients with adrenal incidentalomas. Here we present the first clinical study assessing the performance of t...